-+ 0.00%
-+ 0.00%
-+ 0.00%

Emergent BioSolutions wins $24 million BARDA contract modification for CYFENDUS anthrax vaccine supply

PUBT·09/01/2026 11:55:21
Listen to the news
Emergent BioSolutions wins $24 million BARDA contract modification for CYFENDUS anthrax vaccine supply
  • Emergent BioSolutions received a contract modification valued at about $24 million from BARDA to supply CYFENDUS for U.S. anthrax preparedness.
  • CYFENDUS is an FDA-cleared two-dose anthrax vaccine for post-exposure prophylaxis in adults 18-65 when used with antibacterial drugs.
  • The award extends the company’s U.S. government anthrax vaccine supply work, following a delivery order valued at up to $21.5 million for BioThrax.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609010755PRIMZONEFULLFEED9819049) on September 01, 2026, and is solely responsible for the information contained therein.